Subscribe to our Email Alerts

Amplia Therapeutics Limited

Focal Adhesion Kinase: A New Target in the Fight Against Cancer

Learn more

Amplia Therapeutics Limited

Focus on Fibrotic Cancers and Fibrosis

Learn more

A new approach for treating cancer and fibrotic diseases​

Amplia is a clinical-stage company developing small molecule inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases​.
To view the latest Amplia Therapeutics Limited's Investor Presentation click here Read More

Latest Presentations

Latest ASX Announcements

Media Releases

ASX Share Price

Market Cap:
Price Delay ~20min

Amplia's AMP945 clinical trial in pancreatic cancer, ACCENT, is now recruiting

Amplia Therapeutics recognises and respects First Nations People and welcomes the work of all those who strive for health equality in Australia